GLP-1 Peace Deal! Novo Nordisk and Hims Join Forces

Novo Nordisk and Hims & Hers resolve a patent dispute with a deal giving millions of Americans digital access to branded weight-loss drugs

10 Mar 2026

A lawsuit over copycat weight-loss drugs lasted only weeks. On March 9th Novo Nordisk, a Danish pharmaceutical giant, and Hims & Hers, a fast-growing American telehealth firm, replaced litigation with a partnership. The agreement will allow Hims & Hers to distribute Novo Nordisk’s branded GLP-1 medicines, Wegovy and Ozempic, through its online platform.

The dispute had centred on compounded versions of semaglutide, the active ingredient in both drugs. Novo Nordisk accused Hims & Hers of selling unapproved alternatives while demand for GLP-1 therapies surged across America. Regulators were also circling. The Food and Drug Administration sent warning letters to roughly 30 telehealth companies about compounded GLP-1s, and the Department of Health and Human Services referred Hims & Hers to federal prosecutors over its marketing practices.

Both sides have now stepped back. Hims & Hers will stop promoting compounded GLP-1 alternatives and instead offer Novo Nordisk’s authorised injectable and oral treatments at prices similar to those of rival telehealth providers. Compounded formulations may still be used if a clinician judges them medically necessary. Novo Nordisk has withdrawn its lawsuit, though it retains the right to revive it should the arrangement break down.

Investors welcomed the truce. Shares in Hims & Hers rose by more than 40% after the announcement, with trading volume far above recent norms. Analysts quickly raised their expectations. Needham lifted its price target for the firm to $30 and Citi to $24, arguing that the agreement removes the company’s largest legal and regulatory threat. Demand for the medicines appears strong. Oral Wegovy alone has generated more than 600,000 prescriptions within two months of its launch.

Yet the deal may prompt closer scrutiny. American lawmakers have already asked both companies about prescription volumes, data-sharing and financial ties between drugmakers and telehealth platforms. Researchers at Brown University warn that such partnerships could tilt prescribing decisions towards commercial incentives.

For the moment, however, the arrangement illustrates a broader shift. Telehealth platforms are becoming a major gateway to primary care, and pharmaceutical firms are adapting their distribution accordingly. As demand for GLP-1 drugs continues to climb, the boundary between digital healthcare and drug retailing may grow ever thinner.